China Resources Pharmaceutical Group Limited — Cyborg Score 6/10

Solid
Pharmaceutical Manufacturing, Distribution & Retail

Strategic Profile

The company offers a broad range of chemical drugs, Chinese medicines, and biological drugs across multiple therapeutic areas including cardiovascular, respiratory, orthopedic, and antitumor treatments. It provides warehousing, logistics, and pharmaceutical supply chain solutions to manufacturers, hospitals, distributors, and retail pharmacies.

Cyborg Score Rationale

Established vertically-integrated pharmaceutical business with diversified operations across manufacturing, distribution, and retail. Strong market position as third-largest distributor and stable dividend yield, offset by recent stock price weakness and modest growth trajectory in competitive mainland China market.

Top Insights

  • Vertically integrated model spanning manufacturing, distribution, and retail provides cost efficiency and supply chain control across mainland China
  • Third-largest pharmaceutical distributor by revenue signals significant market scale and established relationships with hospitals and medical institutions
  • Dividend yield of 2.97% indicates shareholder return focus, though stock has declined 20% year-over-year suggesting market skepticism
  • Multi-segment model diversification reduces exposure to single pharmaceutical product cycles and provides revenue stability

Named Competitors

  • Pharmaceutical Distribution and Manufacturing — Chinese pharmaceutical distributor and manufacturer
  • Pharmaceutical Manufacturing and Distribution — Chinese pharmaceutical producer with distribution network
  • Integrated Pharmaceutical Services — Regional competitors in manufacturing, distribution and retail

Recent Developments

  • (March 2026) Current stock price HK$4.59-4.97 range with modest volatility and mixed technical signals
  • (June 2025) Market cap approximately HK$31-32 billion with 52-week trading range of HK$4.61-7.11
  • (August 2025) H1 2025 interim earnings release disclosed representing continued reporting of financial results

Open the full interactive China Resources Pharmaceutical Group Limited report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →